ADDPLAN DF Consortium

consortiapedia.fastercures.org/consortia/addplan-df-consortium/

Research Areas

- Tool Development
  - Clinical Trial
- Biomarker Research
  - Drug

At a Glance

- Status: Active Consortium
- Year Launched: 2013
- Initiating Organization: ICON plc
- Initiator Type: Industry
- Location: North America

Abstract

ADDPLAN® is a stand-alone software, using data to design, simulate, and analyze adaptive clinical trials with ease. The ADDPLAN DF Consortium is comprised of Novartis Pharma AG, Janssen Pharmaceuticals Inc., Eli Lilly, and Aptiv Solutions. The consortium’s objective is to deliver a comprehensive platform and process map for the integrated design and execution of innovative exploratory phase adaptive trials.

Mission

The consortium will work collaboratively to address the challenges that arise in phases II and III of pharmaceutical trials by:

- Developing new statistical methodologies for the design of innovative dose-finding clinical trials with an emphasis on adaptive designs

- Focusing on enhancing the trial execution technologies required to handle the multiple adaptations integral to complex adaptive dose-finding trials
Integrating and validating these methodologies into ADDPLAN DF software for the design, planning, and analysis of dose finding trials, and ensuring that these designs are easily implemented through AptivAdvantage™, the Aptiv Solutions proprietary trial execution platform.

Consortium History

ADDPLAN DF Consortium was founded in 2013.

Structure & Governance

ADDPLAN is adaptive trail design software developed by ICON, a global provider of outsourced drug development services to biopharma, medical device, government, biosimilar, and genetic organizations.

Links/Social Media Feed

Homepage: http://www.iconplc.com/innovation/addplan/addplan-df-consortium/
Twitter: @ICONplc
Facebook: @icon.pic.profile

Points of Contact

Niamh Murphy
Director of Corporate Communications
Tel: +353-1-2912000
Email: Niamh.murphy@iconplc.com
Sponsors & Partners

ICON plc (Sponsor)
Novartis Pharma AG
Janssen Pharmaceuticals Inc.
Eli Lilly
Aptiv Solutions
Pfizer
Roche

Updated: 06/19/2017